Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monique A Hartley-Brown

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Advances in Hematology|July 31, 2010
State-of-the-Art Management of Complications of Myeloma and Its TreatmentMonique A Hartley-Brown, Daniel M Sullivan, Rachid Baz
Cancers|December 23, 2023
Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted TherapyClifton C Mo, Monique A Hartley-Brown, Shonali Midha, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2025
SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in MyelomaClifton C Mo, Yuxin Liu, Monique A Hartley-Brown, et al.
Cancers|March 28, 2024
Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple MyelomaMonique A Hartley-Brown, Clifton C Mo, Omar Nadeem, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 9, 2020
Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decadesDavid W Chitty, Monique A Hartley-Brown, Mersema Abate, et al.
British Journal of Haematology|July 20, 2024
Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidenceMonique A Hartley-Brown, Katja Weisel, Jacopo Bitetti, et al.
Haematologica|November 30, 2023
Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non- Hispanic White race/ethnicity in the United StatesTondre Buck, Monique A Hartley-Brown, Yvonne A Efebera, et al.
Expert Opinion on Drug Safety|October 31, 2023
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myelomaShonali Midha, Monique A Hartley-Brown, Clifton C Mo, et al.
Ejhaem|August 21, 2023
Selinexor: Targeting a novel pathway in multiple myelomaClifton C Mo, Andrew J Yee, Shonali Midha, et al.
Expert Opinion on Emerging Drugs|October 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial dataClifton C Mo, Yuxin Liu, Omar Nadeem, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Advances in Hematology|July 31, 2010
State-of-the-Art Management of Complications of Myeloma and Its TreatmentMonique A Hartley-Brown, Daniel M Sullivan, Rachid Baz
Cancers|December 23, 2023
Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted TherapyClifton C Mo, Monique A Hartley-Brown, Shonali Midha, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2025
SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in MyelomaClifton C Mo, Yuxin Liu, Monique A Hartley-Brown, et al.
Cancers|March 28, 2024
Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple MyelomaMonique A Hartley-Brown, Clifton C Mo, Omar Nadeem, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 9, 2020
Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decadesDavid W Chitty, Monique A Hartley-Brown, Mersema Abate, et al.
British Journal of Haematology|July 20, 2024
Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidenceMonique A Hartley-Brown, Katja Weisel, Jacopo Bitetti, et al.
Haematologica|November 30, 2023
Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non- Hispanic White race/ethnicity in the United StatesTondre Buck, Monique A Hartley-Brown, Yvonne A Efebera, et al.
Expert Opinion on Drug Safety|October 31, 2023
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myelomaShonali Midha, Monique A Hartley-Brown, Clifton C Mo, et al.
Ejhaem|August 21, 2023
Selinexor: Targeting a novel pathway in multiple myelomaClifton C Mo, Andrew J Yee, Shonali Midha, et al.
Expert Opinion on Emerging Drugs|October 30, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial dataClifton C Mo, Yuxin Liu, Omar Nadeem, et al.
Pageof 2